Effect of TXA on Reducing Bruising After Filler Injection
Launched by UNIVERSITY OF WISCONSIN, MADISON · Oct 29, 2024
Trial Information
Current as of June 26, 2025
Not yet recruiting
Keywords
ClinConnect Summary
This clinical trial is studying whether a medication called tranexamic acid (TXA) can help reduce bruising, swelling, and pain after receiving facial filler injections. The primary question the researchers want to answer is if adding TXA to the standard filler treatment can lead to less discomfort and visible bruising for patients. Participants in the study will receive both the facial filler and the TXA, and they will be asked to complete surveys about their experiences.
To be eligible for the trial, participants need to be between the ages of 18 and 89 and interested in getting a facial filler injection. They should also be able to speak English. However, certain individuals will not be able to participate, including those who are pregnant, have specific health conditions related to blood clots, or have a history of significant kidney issues. The trial is not yet recruiting participants, but it aims to gather information that could improve the experience of those receiving facial fillers in the future.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Age equal to or greater than 18 but less than or equal to 89 years.
- • Participants interested in facial filler (HA) injection.
- • English speaking.
- Exclusion Criteria:
- • Minors or under the age of 18
- • Participant over the age of 89
- • Pregnant or breast-feeding women
- • Individuals unable to give consent due to another condition such as impaired decision-making capacity.
- • Individuals with a history of a thrombotic event (DVT, PE, stroke, MI) or genetic disorder that increases risk of thrombosis
- • Concurrent use of estrogen
- • Participants undergoing unilateral facial filler (HA) injection
- • Participants with history of hypersensitivity to TXA or any of the other ingredients
- • Participants that are on current therapeutic anticoagulation therapy and aspirin use
- • Participants with stage 2 or greater renal failure
- • Participants on hemo- or peritoneal dialysis
- • History of diabetes or seizures
- • Current tobacco smokers
- • Acquired defective color vision
About University Of Wisconsin, Madison
The University of Wisconsin-Madison is a leading research institution renowned for its commitment to advancing healthcare through innovative clinical trials. With a strong emphasis on interdisciplinary collaboration, the university leverages its extensive resources, including cutting-edge facilities and a diverse pool of expert researchers, to conduct rigorous studies that address critical health challenges. The institution's focus on translating research findings into practical applications fosters the development of new treatments and interventions, ultimately contributing to improved patient outcomes and public health initiatives. As a sponsor of clinical trials, the University of Wisconsin-Madison is dedicated to upholding the highest ethical standards and ensuring participant safety throughout the research process.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Madison, Wisconsin, United States
Patients applied
Trial Officials
Daniel Cho, MD, PhD
Principal Investigator
University of Wisconsin, Madison
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported